KEYNOTE-905: pembro alone raises a question worth testing. Who might safely need less?

Yüksel Ürün· @DrYukselUrun · X·2026-10-23 20:52· 2 天前评分70

正文 · 原文

KEYNOTE-905: pembro alone raises a question worth testing. Who might safely need less?
@myESMO @FAndreMD @curijoey @DrChoueiri @OncoAlert @OpenMedicineHQ #ESMO26 @Uromigos

581 浏览 · 10 赞 · 8 转发 · 0 回复

会议摘要

4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

来源：Yüksel Ürün · x.com